Affiliation:
1. Department of Medicine University of Virginia Charlottesville Virginia USA
2. Lindner Research Center The Christ Hospital Cincinnati Ohio USA
3. Medtronic, Inc. Mounds View Minnesota USA
4. Heart and Vascular Institute Vanderbilt University Nashville Tennessee USA
Abstract
AbstractBackgroundImplantable cardioverter‐defibrillators are used globally and are reliable, but complications related to transvenous leads remain a concern. Evidence related to the incidence and costs of those complications is heterogeneous with respect to scope and healthcare system. This analysis aims to create estimates of the incidence and costs of tricuspid valve (TV) complications, lead failures, and lead extractions from a single large real‐world data set.Methods and ResultsThis retrospective longitudinal cohort study used the deidentified Medicare Fee for Service administrative claims database. A total of 116 036 patients with de novo transvenous ICD implant were analyzed. Mean hospital costs were $26 903 for tricuspid valve complications, $20 851 for lead failures, and $22 278 for lead extractions.ConclusionsTransvenous ICD lead complications incur significant costs to patients, hospitals, and payers when they occur. Advancements in lead technology that reduce these complications could bring significant clinical and economic value.
Reference4 articles.
1. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society;Al‐Khatib SM;Circulation,2017
2. The Implantable Cardioverter-Defibrillator Lead: Principles, Progress, and Promises
3. Transcatheter Tricuspid Valve Replacement With the EVOQUE System
4. Efficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator